Citizens Business Bank Decreases Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Citizens Business Bank lowered its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 0.6% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 11,089 shares of the medical research company’s stock after selling 62 shares during the period. Citizens Business Bank’s holdings in IQVIA were worth $2,628,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently modified their holdings of IQV. PGGM Investments raised its holdings in shares of IQVIA by 55.8% during the second quarter. PGGM Investments now owns 12,073 shares of the medical research company’s stock valued at $2,553,000 after acquiring an additional 4,326 shares during the last quarter. Simplify Asset Management Inc. boosted its stake in IQVIA by 67.8% during the 3rd quarter. Simplify Asset Management Inc. now owns 9,637 shares of the medical research company’s stock worth $2,284,000 after purchasing an additional 3,894 shares during the last quarter. Raymond James & Associates grew its holdings in shares of IQVIA by 0.7% during the second quarter. Raymond James & Associates now owns 800,374 shares of the medical research company’s stock worth $169,231,000 after buying an additional 5,417 shares in the last quarter. Versor Investments LP acquired a new stake in shares of IQVIA in the third quarter valued at about $1,328,000. Finally, Gradient Investments LLC lifted its stake in shares of IQVIA by 15.6% in the second quarter. Gradient Investments LLC now owns 45,401 shares of the medical research company’s stock worth $9,600,000 after buying an additional 6,134 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Price Performance

IQVIA stock opened at $203.31 on Wednesday. The company has a debt-to-equity ratio of 1.76, a quick ratio of 0.81 and a current ratio of 0.81. The company has a market capitalization of $36.90 billion, a price-to-earnings ratio of 26.68, a price-to-earnings-growth ratio of 2.08 and a beta of 1.49. The company’s 50 day simple moving average is $214.57 and its 200-day simple moving average is $224.96. IQVIA Holdings Inc. has a 1 year low of $187.62 and a 1 year high of $261.73.

Analyst Upgrades and Downgrades

IQV has been the subject of several research reports. JPMorgan Chase & Co. dropped their price objective on shares of IQVIA from $279.00 to $240.00 and set an “overweight” rating for the company in a research note on Tuesday, November 5th. Robert W. Baird dropped their price target on IQVIA from $213.00 to $212.00 and set a “neutral” rating for the company in a research report on Wednesday. Barclays reduced their price objective on IQVIA from $260.00 to $255.00 and set an “overweight” rating on the stock in a research report on Friday, November 1st. Morgan Stanley dropped their target price on IQVIA from $280.00 to $265.00 and set an “overweight” rating for the company in a report on Monday, November 4th. Finally, StockNews.com lowered IQVIA from a “buy” rating to a “hold” rating in a report on Thursday, November 28th. Five analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, IQVIA currently has a consensus rating of “Moderate Buy” and an average target price of $255.81.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.